Don't Take a Position in HealthEquity (HQY)Without Knowing Its Fundamentals!

By Chris Stiles • Thursday, December 15 09:58 • Permanent Link

HealthEquity logged a -3.2% change during today's morning session, and is now trading at a price of $61.01 per share. The S&P 500 index moved -1.9% and the Dow Industrial Average posted a -2.4% change. HQY's trading volume is 66,552 compared to the stock's average volume of 891,504.

HealthEquity trades -25.99% away from its average analyst target price of $82.43 per share. The 14 analysts following the stock have set target prices ranging from $68 to $101, and on average have given HealthEquity a rating of buy.

Anyone interested in buying HQY should be aware of the facts below:

HealthEquity has moved 57.3% over the last year, and the S&P 500 logged a change of -14.4%
Based on its trailing earning per share of -0.66, HealthEquity has a trailing 12 month Price to Earnings (P/E) ratio of -92.3 while the S&P 500 average is 15.97
HQY has a forward P/E ratio of 34.3 based on its forward 12 month price to earnings (Eps) of $1.78 per share
The company has a price to earnings growth (PEG) ratio of 1.72 — a number near or below 1 signifying that HealthEquity is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.7 compared to its sector average of 4.07
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States.
Based in Draper, the company has 3,688 full time employees and a market cap of $5,163,874,304.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.